Head to head
Amylyx Pharmaceuticals vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: AMLX · TAK
AMLX
Amylyx Pharmaceuticals
27.43-2.18%
1-year price shape — +103% over the period
Quant Rating B · 95/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
| AMLX | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 27.43 | 18.37 |
| Change today | -2.18% | +1.49% |
| 1-year return | +103.3% | +29.2% |
| Market cap | $3.44B | $58.68B |
| 52-week range | 10.83 – 41.14 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | -19.45 | -55.67 |
| P/E percentile, own 5-yr range | 4th | 4th |
| P/B | 14.39 | 1.23 |
| Dividend yield | 0.00% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | -1.53 | -0.31 |
| Net profit (TTM) | $-192.03M | $-977.54M |
| Revenue (TTM) | $0 | $4.62T |
| Revenue growth (YoY) | -- | +10.2% |
| Gross margin | -42.6% | 65.5% |
| Operating margin | -292.6% | 10.4% |
| Net margin | -345.4% | -3.5% |
| Free cash flow (TTM) | $-126.72M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 91.8% | 51.5% |
| Insider activity (12mo) | 24 buy / 26 sell | 22 buy / 28 sell |
| Short interest (% of float) | 12.1% | 0.1% |
| Analyst consensus | 100% buy (9) | 100% buy (1) |
| Analyst price target | $46 (+67%) | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | B (95) | C (70) |
| Company | ||
| Employees | 136 | 47,029 |
| Founded | 2013 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.